Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

Yilin Chen, Josh J. Carlson, Peter Martin et al.|Value in Health|2024

Cited by 7